 |
|
| Blog results | Results 1 - 10 of about 303,374 for liver cancer. (0.32 seconds) |
| Sorted by relevance Sort by date |
| 19 Nov 2009 The National Institute for Health and Clinical Excellence (NICE) has ruled that sorafenib should not be made routinely available for patients with the most common form of primary liver cancer, advanced hepatocellular carcinoma (HCC). Cancer Research UK - RSS Feed - http://info.cancerresearchuk.org/news/ |
| 19 Nov 2009 by AntiCitizenOne A drug that can prolong the lives of patients with advanced liver cancer has been rejected for use in the NHS in England, Wales and Northern Ireland. The National Institute for Health and Clinical Excellence (NICE) said the cost of ... National Death Service - http://nationaldeathservice.blogspot.com/ - References |
| 18 Nov 2009 by Perez Hilton Apparently, the tumors on Penny's liver are malignant. Though we don't know the extent of the cancer spread, we do know that friends close to her say that Penny is holding her own and is ready to fight hard. ... Celebrity gossip juicy celebrity rumors... - https://perezhilton.com/ - References |
| 19 Nov 2009 Following a further appraisal, the UK's National Institute for Health and Clinical Excellence (NICE) has again decided against recommending the use of German drug major Bayer's Nexavar (sorafenib) under the National Health Service for ... thepharmaletter.com - http://www.thepharmaletter.com/ |
| 19 Nov 2009 People with advanced liver cancer will be denied a new drug on the NHS under latest draft guidance. Sunday Sun - Home - News - http://www.sundaysun.co.uk/news/ |
| 18 Nov 2009 by Andrew Reeves NICE says the drug sorafenib costs too much to make treatment worthwhile - what utter crap, I would like to see the head of NICE, Andrew Dillon go and explain that to the person suffering from liver cancer and their immediate family ... Andrew Reeves' Running Blog - but what... - http://andrewrunning.blogspot.com/ - References |
| 8 hours ago by Tom Smith Dr Harpreet Wasan, a cancer consultant at London's Hammersmith Hospital, said: 'This cancer is not like any other cancer. There is no alternative treatment. Every other drug that has been tried fails to work. via www.dailymail.co.uk. The Right Coast - http://rightcoast.typepad.com/rightcoast/ |
| 19 Nov 2009 A liver cancer drug capable of extending life has been controversially rejected for use by UK patients, on the grounds of cost. According to NICE (the National Institute for Health and Clinical Excellence), at approximately £3000 per ... Pharmaceutical International - http://www.pharmaceutical-int.com/ |
| 19 Nov 2009 by palmettoconservative A liver cancer drug that can extend the life of patients with severe liver cancer was deemed too expensive for use in England, Wales, and Northern Ireland by the National Institute for Health and Clinical Excellence. (NICE) ... Palmetto Conservative - http://palmettoconservative.wordpress.com/ |
| 13 hours ago by Gary But Macmillan Cancer Support said the decision was "a scandal". More than 3000 people are diagnosed with liver cancer every year in the UK and their prognosis is generally poor. Only about 20% of patients are alive one year after ... Sarah's Web Brigade - http://sarahpalininternetcoalitionblogger.blogspot.com/ - References |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
